{
    "eid": "2-s2.0-85159668075",
    "title": "Outcomes of polatuzumab vedotin-containing regimens in real-world setting of relapsed and or refractory diffuse large B-cell lymphoma patients: a matched-control analysis from the Thai Lymphoma Study Group (TLSG)",
    "cover-date": "2023-07-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hematology",
            "@code": "2720",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Diffuse large B-cell lymphoma",
        "Polatuzumab vedotin",
        "Real-world setting",
        "Refractory",
        "Relapse"
    ],
    "authors": [
        "Thanawat Rattanathammethee",
        "Lalita Norasetthada",
        "Udomsak Bunworasate",
        "Kitsada Wudhikarn",
        "Jakrawadee Julamanee",
        "Panarat Noiperm",
        "Theerin Lanamtieng",
        "Pisa Phiphitaporn",
        "Manassamon Navinpipat",
        "Piyapong Kanya",
        "Dusit Jit-ueakul",
        "Somchai Wongkhantee",
        "Thanongsak Suwannathen",
        "Juthatip Chaloemwong",
        "Peerapon Wong",
        "Nisa Makruasi",
        "Archrob Khuhapinant",
        "Kannadit Prayongratana",
        "Pimjai Niparuck",
        "Nonglak Kanitsap",
        "Tawatchai Suwanban",
        "Tanin Intragumtornchai"
    ],
    "citedby-count": 0,
    "ref-count": 44,
    "ref-list": [
        "Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project",
        "Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011",
        "Non-Hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand",
        "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma",
        "CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group",
        "A predictive model for aggressive non-Hodgkin\u2019s lymphoma",
        "Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling",
        "The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma",
        "Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning",
        "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP",
        "Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study",
        "Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma",
        "Genetics and pathogenesis of diffuse large B-cell lymphoma",
        "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era",
        "Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma",
        "Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era",
        "Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation",
        "Management of relapsed diffuse large B-cell lymphoma",
        "Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study",
        "Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial",
        "Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study",
        "Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study",
        "Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: observations from the JULIET, ZUMA-1, and TRANSCEND trials",
        "Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma",
        "Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study",
        "Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)",
        "Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma",
        "Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data",
        "The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms",
        "Revised response criteria for malignant lymphoma",
        "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification",
        "Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies",
        "Sample size calculation for comparing proportions",
        "Real-life experience with the combination of polatuzumab vedotin, rituximab, and bendamustine in aggressive B-cell lymphomas",
        "Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas",
        "Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience",
        "Polatuzumab vedotin for relapsed/refractory aggressive B-cell lymphoma: a multicenter post-marketing analysis",
        "Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL",
        "Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world",
        "A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma",
        "Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma",
        "Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60199578",
            "affilname": "Ramathibodi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199578",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60199575",
            "affilname": "Siriraj Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60199575",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60032250",
            "affilname": "Faculty of Medicine, Chiang Mai University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60032250",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chaing Mai",
            "@id": "60031637",
            "affilname": "Nakornping Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60031637",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60026046",
            "affilname": "Faculty of Medicine, Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026046",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pitsanulok",
            "@id": "60022498",
            "affilname": "Naresuan University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022498",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60022464",
            "affilname": "Chulabhorn Royal Academy",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60022464",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60020352",
            "affilname": "Vajira Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60020352",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60012921",
            "affilname": "Khon Kaen Regional Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012921",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Pathum Thani",
            "@id": "60012521",
            "affilname": "Thammasat University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60012521",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60006964",
            "affilname": "Phramongkutklao College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006964",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Hatyai",
            "@id": "60006314",
            "affilname": "Prince of Songkla University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006314",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005800",
            "affilname": "Faculty of Medicine, Srinakharinwirot University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005800",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60005255",
            "affilname": "Rajavithi Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60005255",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Chiang Rai",
            "@id": "102066915",
            "affilname": "Chiangrai Prachanukroh Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/102066915",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "Thai Society of Hematology"
    ]
}